Sunday, August 3, 2025

9:50 AM - 10:30 AM

Pyrmont Theatre

---

Details

Diabetes management is evolving beyond traditional glycaemic control, including recent expansion of the PBS for earlier treatment. This session uses dapagliflozin as a case study to explore the expanding scope of diabetes therapies, highlighting its emerging roles in cardiovascular and renal protection. Participants will examine the clinical evidence behind these extended benefits, understand the underlying mechanisms, and discuss practical strategies for integrating these advancements into everyday pharmacy practice. Learning objectives - Identify the expanding clinical indications and recent PBS changes for diabetes therapies with a focus on dapagliflozin. - Discuss the clinical evidence supporting dapagliflozin’s benefits in cardiovascular and renal protection. - Describe the evolving role of pharmacists in optimising patient outcomes with advanced diabetes therapies. Competency standards (2016): 3.3, 3.5